These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. In vitro and in vivo targeting properties of iodine-123- or iodine-131-labeled monoclonal antibody 14C5 in a non-small cell lung cancer and colon carcinoma model. Burvenich I, Schoonooghe S, Cornelissen B, Blanckaert P, Coene E, Cuvelier C, Mertens N, Slegers G. Clin Cancer Res; 2005 Oct 15; 11(20):7288-96. PubMed ID: 16243799 [Abstract] [Full Text] [Related]
6. Biodistribution study of 188Re-labeled trisuccin-HuCC49 and trisuccin-HuCC49deltaCh2 conjugates in athymic nude mice bearing intraperitoneal colon cancer xenografts. Safavy A, Khazaeli MB, Safavy K, Mayo MS, Buchsbaum DJ. Clin Cancer Res; 1999 Oct 15; 5(10 Suppl):2994s-3000s. PubMed ID: 10541333 [Abstract] [Full Text] [Related]
10. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo. O'Reilly T, Wartmann M, Brueggen J, Allegrini PR, Floersheimer A, Maira M, McSheehy PM. Cancer Chemother Pharmacol; 2008 Nov 15; 62(6):1045-54. PubMed ID: 18301895 [Abstract] [Full Text] [Related]
11. Improved radioimmunotherapeutic efficacy of an anticarcinoma monoclonal antibody (131I-CC49) when given in combination with gamma-interferon. Greiner JW, Ullmann CD, Nieroda C, Qi CF, Eggensperger D, Shimada S, Steinberg SM, Schlom J. Cancer Res; 1993 Feb 01; 53(3):600-8. PubMed ID: 8425194 [Abstract] [Full Text] [Related]
13. Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature. Tijink BM, Neri D, Leemans CR, Budde M, Dinkelborg LM, Stigter-van Walsum M, Zardi L, van Dongen GA. J Nucl Med; 2006 Jul 01; 47(7):1127-35. PubMed ID: 16818947 [Abstract] [Full Text] [Related]
14. Evaluation of pre-irradiation on monoclonal antibody localization in colon tumor xenografts expressing a cell-associated antigen. Gridley DS, Slater JB, Slater JM. Anticancer Res; 1995 Jul 01; 15(1):99-104. PubMed ID: 7733650 [Abstract] [Full Text] [Related]
15. Novel antitenascin antibody with increased tumour localisation for Pretargeted Antibody-Guided RadioImmunoTherapy (PAGRIT). De Santis R, Anastasi AM, D'Alessio V, Pelliccia A, Albertoni C, Rosi A, Leoni B, Lindstedt R, Petronzelli F, Dani M, Verdoliva A, Ippolito A, Campanile N, Manfredi V, Esposito A, Cassani G, Chinol M, Paganelli G, Carminati P. Br J Cancer; 2003 Apr 07; 88(7):996-1003. PubMed ID: 12671694 [Abstract] [Full Text] [Related]
16. Therapeutic efficacy and tumor dose estimations in radioimmunotherapy of intraperitoneally growing OVCAR-3 cells in nude mice with (211)At-labeled monoclonal antibody MX35. Elgqvist J, Andersson H, Bäck T, Hultborn R, Jensen H, Karlsson B, Lindegren S, Palm S, Warnhammar E, Jacobsson L. J Nucl Med; 2005 Nov 07; 46(11):1907-15. PubMed ID: 16269606 [Abstract] [Full Text] [Related]
17. Biodistribution properties of (111)indium-labeled C-functionalized trans-cyclohexyl diethylenetriaminepentaacetic acid humanized 3S193 diabody and F(ab')(2) constructs in a breast carcinoma xenograft model. Tahtis K, Lee FT, Smyth FE, Power BE, Renner C, Brechbiel MW, Old LJ, Hudson PJ, Scott AM. Clin Cancer Res; 2001 Apr 07; 7(4):1061-72. PubMed ID: 11309358 [Abstract] [Full Text] [Related]